These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 20491003)

  • 1. [Secondary data for budget impact analyses].
    Sindern J; Schröder-Bernhardi D; Slawik L
    Gesundheitswesen; 2010 Jun; 72(6):356-62. PubMed ID: 20491003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
    Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
    J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outpatient antipsychotic treatment and inpatient costs of schizophrenia.
    Marcus SC; Olfson M
    Schizophr Bull; 2008 Jan; 34(1):173-80. PubMed ID: 17578893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients.
    Glazer WM; Ereshefsky L
    J Clin Psychiatry; 1996 Aug; 57(8):337-45. PubMed ID: 8752015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The impact of antipsychotic medication on the incidence and the costs of inpatient treatment in people with schizophrenia: results from a prospective observational study].
    Kilian R; Angermeyer MC
    Psychiatr Prax; 2004 Apr; 31(3):138-46. PubMed ID: 15042477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of conventional antipsychotic medications for patients with schizophrenia in a medicaid population: therapeutic and cost outcomes over 2 years.
    McCombs JS; Luo M; Johnstone BM; Shi L
    Value Health; 2000; 3(3):222-31. PubMed ID: 16464186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Consumption and cost of antipsychotic drugs].
    Pérez J; Marín N; Vallano A; Castells X; Capellà D
    Actas Esp Psiquiatr; 2005; 33(2):110-6. PubMed ID: 15768318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.
    Chen H; Kennedy WK; Dorfman JH; Fincham JE; Reeves J; Martin BC
    Curr Med Res Opin; 2007 Jun; 23(6):1351-65. PubMed ID: 17559734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Annual health outcomes and treatment costs for schizophrenia populations.
    Mauskopf JA; David K; Grainger DL; Gibson PJ
    J Clin Psychiatry; 1999; 60 Suppl 19():14-9; discussion 20-2. PubMed ID: 10507276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.
    Sun SX; Liu GG; Christensen DB; Fu AZ
    Curr Med Res Opin; 2007 Oct; 23(10):2305-12. PubMed ID: 17697454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The functionality and economic costs of outpatients with schizophrenia in Taiwan.
    Lee IH; Chen PS; Yang YK; Liao YC; Lee YD; Yeh TL; Yeh LL; Cheng SH; Chu CL
    Psychiatry Res; 2008 Apr; 158(3):306-15. PubMed ID: 18243334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthcare costs of atypical antipsychotic use for patients with bipolar disorder in a Medicaid programme.
    Qiu Y; Fu AZ; Liu GG; Christensen DB
    Appl Health Econ Health Policy; 2010; 8(3):167-77. PubMed ID: 20408601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoeconomics of schizophrenia in the 21st century.
    Hanson MA
    J Clin Psychiatry; 1999; 60 Suppl 1():26-7; discussion 28-30. PubMed ID: 10037168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications.
    Farley JF; Cline RR; Schommer JC; Hadsall RS; Nyman JA
    Clin Ther; 2008 Aug; 30(8):1524-39; discussion 1506-7. PubMed ID: 18803994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Methodolocical issues of naturalistic observational studies on the economic evaluation of neuroleptic treatment for schizophrenic disease].
    Kilian R; Angermeyer MC; Becker T
    Gesundheitswesen; 2004 Mar; 66(3):180-5. PubMed ID: 15088222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost of depression in Europe.
    Sobocki P; Jönsson B; Angst J; Rehnberg C
    J Ment Health Policy Econ; 2006 Jun; 9(2):87-98. PubMed ID: 17007486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspective and the measurement of costs and benefits for cost-effectiveness analysis in schizophrenia.
    Meltzer D
    J Clin Psychiatry; 1999; 60 Suppl 3():32-5; discussion 36-7. PubMed ID: 10073375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia.
    Revicki DA
    J Psychiatry Neurosci; 1997 Jul; 22(4):256-66. PubMed ID: 9262048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Juvenile obesity and comorbidity type 2 diabetes mellitus (T2 DM) in Germany: development and cost-of-illness analysis].
    Wolfenstetter SB
    Gesundheitswesen; 2006 Oct; 68(10):600-12. PubMed ID: 17099820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.